ERBB2 and cancer: HER3 antibodies can be involved in cancer treatment in combination with compounds targeting EGFR and HER2, endocrine therapeutic agents, and chemotherapeutic agents, but led to resistance to some therapies, including targeted therapy, chemotherapy, radiotherapy, and hormone therapy[8,178].